Bone health in adolescence

Adolescent Medicine: State of the Art Reviews

Volumn 26, Issue 2, 2015, Pages 291-325

  Carey, Dennis E ^a   Golden, Neville H ^b  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADOLESCENT; BONE DENSITY; BONE DISEASES; BONE REMODELING; DIAGNOSTIC IMAGING; FRACTURES, BONE; HUMAN; INCIDENCE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADOLESCENT; BIOMARKERS; BONE DENSITY; BONE DISEASES; BONE REMODELING; DIAGNOSTIC IMAGING; FRACTURES, BONE; HUMANS; INCIDENCE;

EID: 84973408756     PISSN: 19344287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (171)

1. Bailey DA, Wedge JH, McCulloch RG, et al. Epidemiology of fractures of the distal end of the radius in children as associated with growth. J Bone Joint Surg Am. 1989;71:1225-1231
2. Cooper C, Dennison EM, Leufkens HG, et al. Epidemiology of childhood fractures in Britain: a study using the general practice research database. J Bone Miner Res. 2004;19:1976-1981
3. Mäyränpää M, Viljakainen H, Toiviainen-Salo S, et al. Impaired bone health and asymptomatic vertebral compressions in fracture-prone children: a case-control study. J Bone Miner Res. 2012; 27:1413-1424
4. Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011;26:229-238
5. Bellido T. Osteocyte-driven bone remodeling. Calcif Tissue Int. 2014;94:25-34
6. Bailey DA, Faulkner RA, McKay HA. Growth, physical activity, and bone mineral acquisition. Exerc Sport Sci Rev. 1996;24:233-266
7. Bachrach LK. Acquisition of optimal bone mass in childhood and adolescence. Trends Endocrinol Metab. 2001;12:22-28
8. Lewis MK, Blake GM, Fogelman I. Patient dose in dual x-ray absorptiometry. Osteoporos Int. 1994;4:11-15
9. Crabtree NJ, Arabi A, Bachrach LK, et al. Dual-energy X-ray absorptiometry interpretation and reporting in children and adolescents: the revised 2013 ISCD Pediatric Official Positions. J Clin Densitom. 2014;17:225-242
10. Kalkwarf HJ, Zemel BS, Gilsanz V, et al. The bone mineral density in childhood study: bone mineral content and density according to age, sex, and race. J Clin Endocrinol Metab. 2007;92:2087-2099
11. Ward KA, Ashby RL, Roberts SA, et al. UK reference data for the Hologic QDR Discovery dual-energy x ray absorptiometry scanner in healthy children and young adults aged 6-17 years. Arch Dis Child. 2007;92:53-59
12. Horlick M, Wang J, Pierson RN Jr, et al. Prediction models for evaluation of total-body bone mass with dual-energy X-ray absorptiometry among children and adolescents. Pediatrics. 2004;114:e337-e345
13. Zemel BS, Kalkwarf HJ, Gilsanz V, et al. Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study. J Clin Endocrinol Metab. 2011;96:3160-3169
14. Goulding A, Grant AM, Williams SM. Bone and body composition of children and adolescents with repeated forearm fractures. J Bone Miner Res. 2005;20:2090-2096
15. Clark EM, Ness AR, Bishop NJ, et al. Association between bone mass and fractures in children: a prospective cohort study. J Bone Miner Res. 2006;21:1489-1495
16. Kalkwarf HJ, Laor T, Bean JA. Fracture risk in children with a forearm injury is associated with volumetric bone density and cortical area (by peripheral QCT) and areal bone density (by DXA). Osteoporos Int. 2011;22:607-616
17. Gordon CM, Leonard MB, Zemel BS; International Society for Clinical Densitometry. 2013 Pediatric Position Development Conference: executive summary and reflections. J Clin Densitom. 2014;17:219-224
18. Bachrach LK, Sills IN; American Academy of Pediatrics Section on Endocrinology. Clinical report-bone densitometry in children and adolescents. Pediatrics. 2011;127:189-194
19. Beaupre GS. Radiation exposure in bone measurements. J Bone Miner Res. 2006;21:803; author reply 804
20. Genant H, Wu C, vanKuijk C, et al. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137-1148
21. Nguyen TV. Contributions of Genetics and Environmental Factors to the Determinants of Osteoporosis Fractures. PhD Thesis. Garvan University of Medicine, Department of Community Medicine, Faculty of Medicine, The University of New South Wales, Sydney, Australia.1998; 388
22. Pocock NA, Eisman JA, Hopper JL, et al. Genetic determinants of bone mass in adults. A twin study. J Clin Invest. 1987;80:706-710
23. Young D, Hopper JL, Nowson CA, et al. Determinants of bone mass in 10- to 26-year-old females: a twin study. J Bone Miner Res. 1995;10:558-567
24. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995;332:767-773
25. Gilsanz V, Nelson DA. Childhood and adolescence. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Washington, DC: American Society for Bone and Mineral Research; 2003: 71-80
26. Gilsanz V, Skaggs DL, Kovanlikaya A, et al. Differential effect of race on the axial and appendicular skeletons of children. J Clin Endocrinol Metab. 1998;83:1420-1427
27. Lloyd T, Andon MB, Rollings N, et al. Calcium supplementation and bone mineral density in adolescent girls. JAMA. 1993;270:841-844
28. Wyshak G. Teenaged girls, carbonated beverage consumption, and bone fractures. Arch Pediatr Adolesc Med. 2000;154:610-613
29. Bachrach LK, Katzman DK, Litt IF, et al. Recovery from osteopenia in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab. 1991;72:602-606
30. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16:101-116
31. van Dijk F, Byers P, Dalgleish R, et al. EMQN best practice guidelines for the laboratory diagnosis of osteogenesis imperfecta. Eur J Hum Genet. 2012;20:1-9
32. Dent CE. Osteoporosis in childhood. Postgrad Med J. 1977;53:450-457
33. Rauch F, Bishop N. Juvenile osteoporosis. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Washington, DC: American Society for Bone and Mineral Research; 2007:293-302
34. Soyka LA, Grinspoon S, Levitsky LL, et al. The effects of anorexia nervosa on bone metabolism in female adolescents. J Clin Endocrinol Metab. 1999;84:4489-4496
35. Grinspoon S, Thomas E, Pitts S, et al. Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. Ann Intern Med. 2000;133:790-794
36. Golden NH, Lanzkowsky L, Schebendach J, et al. The effect of estrogen-progestin treatment on bone mineral density in anorexia nervosa. J Pediatr Adolesc Gynecol. 2002;15:135-143
37. Soyka LA, Misra M, Frenchman A, et al. Abnormal bone mineral accrual in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab. 2002;87:4177-4185
38. Misra M, Aggarwal A, Miller KK, et al. Effects of anorexia nervosa on clinical, hematologic, biochemical, and bone density parameters in community-dwelling adolescent girls. Pediatrics. 2004;114:1574-1583
39. Misra M, Katzman DK, Cord J, et al. Bone metabolism in adolescent boys with anorexia nervosa. J Clin Endocrinol Metab. 2008;93:3029-3036
40. Lucas AR, Melton LJ 3rd, Crowson CS, et al. Long-term fracture risk among women with anorexia nervosa: a population-based cohort study. Mayo Clin Proc. 1999;74:972-977
41. Vestergaard P, Emborg C, Stoving RK, et al. Fractures in patients with anorexia nervosa, bulimia nervosa, and other eating disorders-a nationwide register study. Int J Eat Disord. 2002;32:301-308
42. Miller KK, Lee EE, Lawson EA, et al. Determinants of skeletal loss and recovery in anorexia nervosa. J Clin Endocrinol Metab. 2006;91:2931-2937
43. Naessen S, Carlstrom K, Glant R, et al. Bone mineral density in bulimic women-influence of endocrine factors and previous anorexia. Eur J Endocrinol. 2006;155:245-251
44. Rigotti NA, Neer RM, Skates SJ, et al. The clinical course of osteoporosis in anorexia nervosa. A longitudinal study of cortical bone mass. JAMA. 1991;265:1133-1138
45. Misra M, Prabhakaran R, Miller KK, et al. Weight gain and restoration of menses as predictors of bone mineral density change in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab. 2008;93:1231-1237
46. Klibanski A, Biller BM, Schoenfeld DA, et al. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J Clin Endocrinol Metab. 1995;80:898-904
47. Strokosch GR, Friedman AJ, Wu SC, et al. Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in adolescent females with anorexia nervosa: a double-blind, placebo-controlled study. J Adolesc Health. 2006;39:819-827
48. Misra M, Katzman D, Miller KK, et al. Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. J Bone Miner Res. 2011;26:2430-2438
49. Nattiv A, Loucks AB, Manore MM, et al. American College of Sports Medicine position stand. The female athlete triad. Med Sci Sports Exerc. 2007;39:1867-1882
50. Pollock N, Grogan C, Perry M, et al. Bone-mineral density and other features of the female athlete triad in elite endurance runners: a longitudinal and cross-sectional observational study. Int J Sport Nutr Exerc Metab. 2010;20:418-426
51. Nichols JF, Rauh MJ, Lawson MJ, et al. Prevalence of the female athlete triad syndrome among high school athletes. Arch Pediatr Adolesc Med. 2006;160:137-142
52. Barrack MT, Gibbs JC, De Souza MJ, et al. Higher incidence of bone stress injuries with increasing female athlete triad-related risk factors: a prospective multisite study of exercising girls and women. Am J Sports Med. 2014;42:949-958
53. Cromer BA, Stager M, Bonny A, et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health. 2004;35:434-441
54. Scholes D, LaCroix AZ, Ichikawa LE, et al. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med. 2005;159:139-144
55. Cromer BA, Scholes D, Berenson A et al. Depot medroxyprogesterone acetate and bone mineral density in adolescents-the Black Box Warning: a Position Paper of the Society for Adolescent Medicine. J Adolesc Health. 2006;39:296-301
56. American College of Obstetricians and Gynecologists Committee on Adolescent Health Care and Committee on Gynecologic Practice. ACOG Committee Opinion No. 415: Depot medroxyprogesterone acetate and bone effects. Obstet Gynecol. 2008;112:727-730
57. Cibula D, Skrenkova J, Hill M, et al. Low-dose estrogen combined oral contraceptives may negatively influence physiological bone mineral density acquisition during adolescence. Eur J Endocrinol. 2012;166:1003-1011
58. Scholes D, Hubbard RA, Ichikawa LE, et al. Oral contraceptive use and bone density change in adolescent and young adult women: a prospective study of age, hormone dose, and discontinuation. J Clin Endocrinol Metab. 2011;96:E1380-1387
59. Lopez LM, Chen M, Mullins S, et al. Steroidal contraceptives and bone fractures in women: evidence from observational studies. Cochrane Database Syst Rev. 2012;8:CD009849
60. Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9:30-54
61. Weinstein RS, Jilka RL, Parfitt AM, et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102:274-282
62. Yao W, Cheng Z, Busse C, et al. Glucocorticoid excess in mice results in early activation of osteo-clastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum. 2008;58:1674-1686
63. Manolagas SC. Corticosteroids and fractures: a close encounter of the third cell kind. J Bone Miner Res. 2000;15:1001-1005
64. Canalis E, Bilezikian JP, Angeli A, et al. Perspectives on glucocorticoid-induced osteoporosis. Bone. 2004;34:593-598
65. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777-787
66. Sambrook PN. Glucocorticoid-induced osteoporosis. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Washington, DC: American Society for Bone and Mineral Research; 2006:296-302
67. Pappa H, Thayu M, Sylvester F, et al. A clinical report on skeletal health of children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;53:11-25
68. Loftus EV Jr, Crowson CS, Sandborn WJ, et al. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology. 2002;123:468-475
69. Loftus EV Jr, Achenbach SJ, Sandborn WJ, et al. Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2003;1:465-473
70. Siffledeen JS, Siminoski K, Jen H, et al. Vertebral fractures and role of low bone mineral density in Crohn's disease. Clin Gastroenterol Hepatol. 2007;5:721-728
71. Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in United States: a large multicenter study. Arch Inter Med. 2003;163:286-292
72. Bennett TI, Hunter D, Vaugham JM. Idiopathic steatorrhea. A nutritional disturbance associated with tetany, osteomalacia and anaemia. Q J Med. 1932;1:603-677
73. Holms WH, Starr P. A nutritional disturbance in adults resembling coeliac disease and sprue: emaciation, anemia, tetany, chronic diarrhea and malabsorption of fat. JAMA. 1929;92:975-980
74. Salvesen HA, Boe J. Osteomalacia in sprue. Acta M Scan. 1953;146:290-299
75. Kemppainen T, Kroger H, Janatuinen E, et al. Osteoporosis in adult patients with celiac disease. Bone. 1999;24:249-255
76. Meyer D, Stavropolous S, Diamond B, et al. Osteoporosis in a North American adult population with celiac disease. Am J Gastroenterol. 2001;96:112-119
77. Turner J, Pellerin G, Mager D. Prevalence of metabolic bone disease in children with celiac disease is independent of symptoms at diagnosis. J Pediatr Gastroenterol Nutr. 2009;49:589-593
78. Fouda MA, Khan AA, Sultan M, et al. Evaluation and management of skeletal health in celiac disease: Position statement. Can J Gastroenterol. 2012;26(11):819-829
79. Ludvigsson JF, Michaelsson K, Ekbom A, et al. Coeliac disease and the risk of fractures: a general population-based cohort study. Aliment Pharmacol Ther. 2007;25:273-285
80. Lewiecki EM, Watts NB, McClung MR, et al. Official positions of the international society for clinical densitometry. J Clin Endocrinol Metab. 2004;89:3651-3655
81. Henderson RC, Madsen CD. Bone mineral content and body composition in children and young adults with cystic fibrosis. Pediatr Pulmonol. 1999;27:80-84
82. Aris RM, Merkel PA, Bachrach LK, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab. 2005;90:1888-1896
83. Hecker TM, Aris RM. Management of osteoporosis in adults with cystic fibrosis. Drugs. 2004;64:133-147
84. Haworth CS, Selby PL, Webb AK, et al. Inflammatory related changes in bone mineral content in adults with cystic fibrosis. Thorax. 2004;59:613-617
85. Ionescu AA, Nixon LS, Evans WD, et al. Bone density, body composition, and inflammatory status in cystic fibrosis. Am J Respir Crit Care Med. 2000;162:789-794
86. Papaioannou A, Kennedy CC, Freitag A, et al. Longitudinal analysis of vertebral fracture and BMD in a Canadian cohort of adult cystic fibrosis patients. BMC Musculoskelet Disord. 2008;9:125
87. Hardin DS, Ahn C, Prestidge C, et al. Growth hormone improves bone mineral content in children with cystic fibrosis. J Pediatr Endocrinol Metab. 2005;18:589-595
88. Almeida M, Han L, Ambrogini E, et al. Glucocorticoids and tumor necrosis factor alpha increase oxidative stress and suppress Wnt protein signaling in osteoblasts. J Biol Chem. 2011;286:44326-44335
89. Okamoto K, Takayanagi H. Regulation of bone by the adaptive immune system in arthritis. Arthritis Res Ther. 2011;13:219
90. Henderson CJ, Cawkwell GD, Specker BL, et al. Predictors of total body bone mineral density in non-corticosteroid-treated prepubertal children with juvenile rheumatoid arthritis. Arthritis Rheum. 1997;40:1967-1975
91. Huber AM, Gaboury I, Cabral DA, et al. Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Consortium. Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders. Arthritis Care Res. 2010;62:516-526
92. Rodd C, Lang B, Ramsay T, et al. Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study. Arthritis Care Res. 2012;64:122-131
93. LeBlanc C, Ma J, Scuccimarri R, et al. Glucocorticoid therapy and the risk of incident vertebral fractures in children with rheumatic disorders. Arthritis Rheumatol. 2014;66(Suppl 3):S199-S200
94. Winkel ML, Pieters R, Hop WCJ, et al. Bone mineral density at diagnosis determines fracture rate in children with acute lymphoblastic leukemia treated according to the DCOG-ALL9 protocol. Bone. 2014;59:223-228
95. Haddy TB, Mosher RB, Reaman GH. Osteoporosis in survivors of acute lymphoblastic leukemia. Oncologist. 2001;6:278-285
96. Mostoufi-Moab S, Brodsky J, Isaacoff E, et al. Longitudinal assessment of bone density and structure in childhood survivors of acute lymphoblastic leukemia without cranial radiation. J Clin Endocrinol Metab. 212:97;3584-3592
97. Bakalov VK, Chen ML, Baron J, et al. Bone mineral density and fractures in Turner syndrome. Am J Med. 2003;115:259-264
98. Bakalov VK, Axelrod L, Baron J, et al. Selective reduction in cortical bone mineral density in Turner syndrome independent of ovarian hormone deficiency. J Clin Endocrinol Metab. 2003;88:5717-5722
99. Rubin K. Turner syndrome and osteoporosis: mechanisms and prognosis. Pediatrics. 1998;102(2 Pt 3):481-485
100. Hough JP, Boyd RN, Keating JL. Systematic review of interventions for low bone mineral density in children with cerebral palsy. Pediatrics. 2010;125(3):e670-e678
101. Mergler S, Evenhuis HM, Boot AM. Epidemiology of low bone mineral density and fractures in children with severe cerebral palsy: a systematic review. Dev Med Child Neurol. 2009:51;773-778
102. Henderson RC, Lark RK, Gurka MJ, et al. Bone density and metabolism in children and adolescents with moderate to severe cerebral palsy. Pediatrics. 2002;110(1 Pt 1):e5
103. Henderson RC. Bone density and other possible predictors of fracture risk in children and adolescents with spastic quadriplegia. Dev Med Child Neurol. 1997;39:224-227
104. Golden NH, Abrams SA; American Academy of Pediatrics Committee On Nutrition. Optimizing bone health in children and adolescents. Pediatrics. 2014;134:e1229-e1243
105. US Department of Agriculture, Agricultural Research Service. Data tables: results from USDA's 1994-96 Continuing Survey of Food Intakes by Individuals and 1994-96 Diet and Knowledge Survey.1999. Available at: www.ars.usda.gov/services/docs.htm?docid57760. Accessed April 7, 2013
106. Suitor CW, Gleason PM. Using dietary reference intake-based methods to estimate the prevalence of inadequate nutrient intake among school-aged children. J Am Diet Assoc. 2002:102:530-536
107. Matkovic V, Ilich JZ. Calcium requirements for growth: are current recommendations adequate? Nutr Rev.1993;51:171-180
108. Jackman LA, Millane SS, Martin BR, et al. Calcium retention in relation to calcium intake and postmenarcheal age in adolescent females. Am J Clin Nutr. 1997;66:327-333
109. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-281
110. Institute of Medicine. 2011 Dietary Reference Intakes for Calcium and Vitamin D. Washington DC: The National Academies Press; 2011
111. Misra M, Pacaud D, Petryk A, et al. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics. 2008;122:398-417
112. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911-1930
113. Gallagher JC, Riggs BL, Eisman J, et al. Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: effect of age and dietary calcium. J Clin Invest. 1979;64:729-736
114. Boucher-Berry C, Speiser PW, Carey DE, et al. Vitamin D, osteocalcin, and risk for adiposity as comorbidities in middle school children. J Bone Mineral Res. 2012;27:283-293
115. Bedner M, Lippa KA, Tai SS. An assessment of 25-hydroxyvitamin D measurements in comparability studies conducted by the Vitamin D Metabolites Quality Assurance Program. Clin Chim Acta. 2013;426:6-11
116. Fraser WD, Milan AM. Vitamin D assays: past and present debates, difficulties, and developments. Calcif Tissue Int. 2013;92:118-127
117. Wyness SP, Straseski JA. Performance characteristics of six automated 25-hydroxyvitamin D assays: mind your 3's and 2's. Poster session presented at the Endocrine Society's 96th Annual Meeting (ENDO), Chicago, Illionois, 2014
118. He CS, Gleeson M, Fraser WD. Measurement of circulating 25-hydroxy vitamin D using three commercial enzyme-linked immunosorbent assay kits with comparison to liquid chromatography: tandem mass spectrometry method. ISRN Nutr. 2013;13:723139
119. Heaney RP 1, Recker RR, Grote J, et al. Vitamin D(3) is more potent than vitamin D(2) in humans. J Clin Endocrinol Metab. 2011;96:E447-E452
120. Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab. 2008;93:677-681
121. MacKelvie KJ, Khan KM, Petit MA, et al. A school-based exercise intervention elicits substantial bone health benefits: a 2-year randomized controlled trial in girls. Pediatrics. 2003;112(6 Pt 1):e447
122. McKay H, MacLean L, Petit MA, et al. “Bounce at the Bell”: a novel program of short bouts of exercise improves proximal femur bone mass in early pubertal children. Br J Sports Med. 2005;39:521-526
123. Snow-Harter C, Bouxsein ML, Lewis BT, et al. Effects of resistance and endurance exercise on bone mineral status of young women: a randomized exercise intervention trial. J Bone Miner Res. 1992;7:761-769
124. Tangpricha V, Kelly A, Stephenson A, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab. 2012;97:1082-1093
125. Sonneville KR, Gordon CM, Kocher MS, et al. Vitamin D, calcium, and dairy intakes and stress fractures among female adolescents. Arch Pediatr Adolesc Med. 2012;166:595-600
126. Lapatsanis D, Moulas A, Cholevas V, et al. Vitamin D: a necessity for children and adolescents in Greece. Calcif Tissue Int. 2005;77:348-355
127. Dong Y, Pollock N, Stallmann-Jorgensen IS, et al. Low 25-hydroxyvitamin D levels in adolescents: race, season, adiposity, physical activity, and fitness. Pediatrics. 2010;125:1104-1111
128. Harkness LS, Cromer BA. Vitamin D deficiency in adolescent females. J Adolesc Health. 2005;37:75
129. Gordon CM, DePeter KC, Feldman HA, et al. Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med. 2004;158:531-537
130. Looker AC, Dawson-Hughes B, Calvo MS, et al. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone. 2002;30:771-777
131. Powe CE, Evans MK, Wenger J, et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med. 2013;369:1991-2000
132. Harel Z, Flanagan P, Forcier M, et al. Low vitamin D status among obese adolescents: prevalence and response to treatment. J Adolesc Health. 2011;48:448-452
133. Turer CB, Lin H, Flores G. Prevalence of vitamin D deficiency among overweight and obese US children. Pediatrics. 2013;131:e152-e161
134. Wortsman J, Matsuoka LY, Chen TC, et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000;72:690-693
135. Kremer R, Campbell RP, Reinhardt T, et al. Vitamin D status and its relationship to body fat, final height, and peak bone mass in young women. J Clin Endocrinol Metab. 2009;94:67-73
136. Lenders CM, Feldman HA, Von Scheven E, et al; Elizabeth Glaser Pediatric Research Network Obesity Study Group. Relation of body fat indexes to vitamin D status and deficiency among obese adolescents. Am J Clin Nutr. 2009;90:459-467
137. Root AW, Diamond FB. Disorders of mineral homeostasis the newborn, infant, child and adolescent. In: Sperling MA, ed. Pediatric Endocrinology. 3rd ed. Philadelphia, PA: Saunders Elsevier; 2008:686-769
138. Pettifor JM. Nutritional rickets. In: Glorieux FH, Pettifor JM, Juppner H, eds. Pediatric Bone: Biology & Diseases. San Diego, CA: Academic Press; 2003:541-566
139. Pappa HM, Mitchell PD, Jiang H, et al. Treatment of vitamin D insufficiency in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing three regimens. J Clin Endocrinol Metab. 2012;97:2134-2142
140. Lorenzo J, ed. How much calcium and vitamin D? The American Society for Bone and Mineral Research. March 27, 2013. Available at: community.asbmr.org/index.php?/topic/1188-how-much-calcium-and-vitamin-d/. Accessed May 13, 2015
141. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006:354;669-683
142. US Preventive Services Task Force. Final Recommendation Statement: Vitamin D and Calcium to Prevent Fractures: Preventive Medication, February 2013. Available at: http://www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/vitamin-d-and-calcium-to-prevent-fractures-preventive-medication?ds=1&s=vitamin%20d%20and%20calcium. Accessed April 7, 2013
143. Bertelloni S, Baroncelli GI, Ferdeghini M, et al. Normal volumetric bone mineral density and bone turnover in young men with histories of constitutional delay of puberty. J Clin Endocrinol Metab. 1998;83:4280-4283
144. Speiser PW, Clarson CL, Eugster EA, et al. Bisphosphonate treatment of pediatric bone disease. Pediatr Endocrinol Rev. 2005;3:87-96
145. Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947-952
146. Rauch F, Cornibert S, Cheung M, et al. Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone. 2007;40:821-827
147. Shapiro JR, McCarthy EF, Rossiter K, et al. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry and parameters of bone turnover in adults with type IA osteogenesis imperfecta. Calcif Tissue Int. 2003;27:103-112
148. Ward LM, Rauch F, Whyte MP, et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab. 2011;96:355-364
149. Bishop N, Adami S, Ahmed S, et al. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1424-1432
150. Ward L, Rauch F. Oral bisphosphonates for paediatric osteogenesis imperfecta? Lancet. 2013;382:1388-1389
151. Steelman J, Zeitler P. Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J Pediatr. 2003;142:417-423
152. Ward L, Tricco AC, Phuong P, et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev. 2007;4:CD005324
153. Bachrach LK, Ward LM. Clinical review 1: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab. 2009;94:400-409
154. Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373:1253-1263
155. Golden NH, Iglesias EA, Jacobson MS, et al. Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2005;90:3179-3185
156. Miller KK, Meenaghan E, Lawson EA, et al. Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2011;96:2081-2088
157. Henderson RC, Lark RK, Kecskemethy HH, et al. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr. 2002;141:644-651
158. Ward KA, Adams JE, Freemont TJ, et al. Can bisphosphonate treatment be stopped in a growing child with skeletal fragility? Osteoporos Int. 2007;18:1137-1140
159. Black D, Rosen CJ. Bisphosphonates for prevention and Treatment of Osteoporosis. Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Washington, DC: American Society for Bone and Mineral Research; 2006:277-282
160. Graepel P, Bentley P, Fritz H, et al. Reproduction toxicity studies with pamidronate. Arzneimittel-forschung. 1992;42:654-667
161. Brumsen C, Hamdy T, Neveen A, et al. Long-term effects of bisphosphonates on the growing skeleton: studies of young patients with severe osteoporosis. Medicine. 1997;76:266-283
162. Djokanovic N, Klieger-Grossmann C, Koren G. Does treatment with bisphosphonates endanger the human pregnancy? J Obstet Gynaecol Can. 2008;30:1146-1148
163. Kauffman RP, Overton TH, Shiflett M, et al. Osteoporosis in children and adolescent girls: case report of idiopathic juvenile osteoporosis and review of the literature. Obstet Gynecol Surv. 2001;56:492-504
164. Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonate-induced osteopetrosis. N Engl J Med. 2003;349:457-463
165. Munns CF, Rauch F, Zeitlin L, et al. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res. 2004;19:1779-1786
166. Bilezikian JP. Osteonecrosis of the jaw-do bisphosphonates pose a risk? N Engl J Med. 2006;355:2278-2281
167. Brown JJ, Ramalingam L, Zacharin MR. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children? Clin Endocrinol (Oxf). 2008;68:863-867
168. Neer RM, Arnaud CD. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441
169. Riggs BL, Parfitt AM. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res. 2005;20:177-184
170. Brown J, Prince R, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009:24;153-161
171. Costa A, Bilezikian J. Sclerostin: therapeutic horizons based upon its actions. Curr Osteoporos Rep. 2012;10:64-72